Pharma BD Deal Intelligence
Biogen Inc. / Vanqua Bio, Inc.
2025 · Licensing/Option · $1.1B · Complete
Biogen licensed exclusive worldwide rights to Vanqua Bio's preclinical oral small-molecule C5aR1 antagonist, designed to modulate neutrophil-driven inflammation, expanding Biogen's immunology portfolio. Vanqua Bio receives USD 70 million upfront and is eligible for up to USD 990 million in development, regulatory, commercial and sales milestones plus tiered royalties on net sales. Biogen recorded the upfront as acquired IPR&D expense in Q4 2025.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Oct 24, 2025
- Deal value $1.1B
- Deal type Licensing/Option
- Therapeutic area Immunology
- Key assets Oral C5aR1 antagonist (preclinical)
- Mechanism Oral small-molecule C5aR1 (complement C5a receptor 1) antagonist
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · Biogen Inc. deals · Immunology deals